CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-17 | Epperly Melissa B, Director | Grant or award | +670 | 16,474 | ||
| 2026-04-17 | MOMTAZEE JAMES C Director | Grant or award | +469 | 109,499 | ||
| 2026-04-17 | MOMTAZEE JAMES C Director | Shares withheld for taxes | −94 | $29.83 | $3K | 109,405 |
| 2026-04-17 | Oren Ilan Director | Grant or award | +896 | 120,324 | ||
| 2026-04-17 | Oren Ilan Director | Shares withheld for taxes | −95 | $29.83 | $3K | 120,229 |
| 2026-04-16 | Gline Matthew CEO | Sale | −289,774 | $29.16 | $8.4M | 16,736,116 |
| 2026-04-08 | Humes Jennifer Chief Accounting Officer | Sale | −13,538 | $28.37 | $384K | 84,191 |
| 2026-03-31 | Torti Frank President and Vant Chair | Shares withheld for taxes | −160,035 | $27.70 | $4.4M | 13,576,512 |
| 2026-03-31 | Gline Matthew CEO | Shares withheld for taxes | −304,684 | $27.70 | $8.4M | 17,025,890 |
| 2026-03-31 | Sukhatme Mayukh President & CIO | Shares withheld for taxes | −187,512 | $27.70 | $5.2M | 18,677,617 |
| 2026-03-30 | Gline Matthew CEO | Option exercise | +97,319 | 17,384,400 | ||
| 2026-03-30 | Gline Matthew CEO | Shares withheld for taxes | −53,826 | $26.41 | $1.4M | 17,330,574 |
| 2026-03-30 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights | −2,178,150 | $11.50 | $25.0M | 0 |
| 2026-03-30 | Sukhatme Mayukh President & CIO | Option exercise | +58,391 | 18,894,938 | ||
| 2026-03-30 | Sukhatme Mayukh President & CIO | Shares withheld for taxes | −29,809 | $26.41 | $787K | 18,865,129 |
| 2026-03-30 | Sukhatme Mayukh President & CIO | Option exercise · Capped Value Appreciation Rights | −1,306,889 | $11.50 | $15.0M | 0 |
| 2026-03-26 | Fitzgerald Meghan Director | Option exercise | +70,000 | $8.80 | $616K | 112,963 |
| 2026-03-26 | Fitzgerald Meghan Director | Sale | −70,000 | $27.45 | $1.9M | 42,963 |
| 2026-03-26 | Fitzgerald Meghan Director | Option exercise · Stock Option (Right to Buy) | −70,000 | 48,578 | ||
| 2026-03-20 | Pulik Richard CFO | Shares withheld for taxes | −1,546 | $27.70 | $43K | 236,867 |
Page 9 of 29 · 570 trades